Ixazomib NEW
| Price | $41 | $96 | $129 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: Ixazomib | CAS No.: 1072833-77-2 |
| Purity: 99.49% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | Ixazomib |
| Description | Ixazomib (MLN2238) , a second generation, boron-containing peptide proteasome inhibitor (PI), inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome (IC50/Ki: 3.4/0.93 nM, in cell-free assays), also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50: 31/3500 nM). |
| Cell Research | Calu-6 cells are cultured in MEM containing 10% FBS and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. For IC50 determinations, cells are treated with varying concentrations of Bortezomib or MLN2238 in DMSO (0.5% final, v/v) for 1 hour at 37 °C. For reversibility experiments, cells are treated with either 1 μM Bortezomib or MLN2238 for 30 minutes at 37 °C and then washed thrice in medium to remove the Bortezomib or MLN2238. Cells are incubated for an additional 4 hours at 37 °C, after which the medium is removed and replaced with fresh medium. (Only for Reference) |
| Kinase Assay | Kinase assay : Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument. |
| In vitro | MLN2238 is a biologically active metabolite of MLN9708.MLN2238 and Bortezomib are both time-dependent reversible inhibitors of the proteasome, but the isolated half-life of the proteasomal effect of MLN2238 (18 min) is 6-fold faster compared with that of Bortezomib (110 min).The oncological efficacy of MLN2238 is higher than that of Bortezomib. MLN2238 is a nitrogen-terminally capped dipeptide leucine borate that inhibits the hydrolysis site of chymotrypsin-like enzymes in the 20S proteasome (IC50/Ki: 3.4/0.93 nM). At higher concentrations, MLN2238 also inhibited the caspase-like hydrolysis site (IC50: 31 nM) and the trypsin-like hydrolysis site (IC50: 3.5 μM) of the 20S proteasome.MLN2238 inhibited Calu-6 cells (IC50: 9.7 nM). |
| In vivo | MLN2238 is a biologically active metabolite of MLN9708.MLN2238 and Bortezomib are both time-dependent reversible inhibitors of the proteasome, but the isolated half-life of the proteasomal effect of MLN2238 (18 min) is 6-fold faster compared with that of Bortezomib (110 min).The oncological efficacy of MLN2238 is higher than that of Bortezomib. MLN2238 is a nitrogen-terminally capped dipeptide leucine borate that inhibits the hydrolysis site of chymotrypsin-like enzymes in the 20S proteasome (IC50/Ki: 3.4/0.93 nM). At higher concentrations, MLN2238 also inhibited the caspase-like hydrolysis site (IC50: 31 nM) and the trypsin-like hydrolysis site (IC50: 3.5 μM) of the 20S proteasome.MLN2238 inhibited Calu-6 cells (IC50: 9.7 nM). |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.54 mM), Sonication is recommended. DMSO : 55 mg/mL (152.34 mM), Sonication is recommended. Ethanol : 9 mg/mL (24.93 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | Proteasome | MLN-2238 | MLN 2238 | Ixazomib | Inhibitor | inhibit | caspase-like (β1) | Autophagy | 20S proteasome |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Orally Active Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-17 | ||
| $6.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2026-07-09 | |
| $2.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY